Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABX1200
- Development stage
- Preclinical
- Lead developer
- Aro Biotherapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ABX1200 is a therapeutic candidate developed by Aro Biotherapeutics utilizing their proprietary Centyrin platform technology. It is designed to target CD40, a co-stimulatory protein found on antigen-presenting cells, to modulate immune signaling. The drug consists of a Centyrin scaffold that enables the targeted delivery of oligonucleotides or other drug payloads specifically to CD40-expressing cells. This approach aims to treat various immune-mediated and inflammatory diseases, including myositis, multiple sclerosis, Sjogren's syndrome, and transplant rejection, by precisely intervening in the CD40-CD40L pathway.
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on ABX1200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABX1200.